Catalyst Pharmaceuticals appoints Dr. Daniel Curran to its Board, enhancing expertise in rare disease therapies and business development.
Quiver AI Summary
Catalyst Pharmaceuticals, Inc. has appointed Dr. Daniel Curran to its Board of Directors. Dr. Curran brings over 25 years of pharmaceutical experience, particularly in strategy and business development, and currently serves as Managing Partner at Mountainfield Venture Partners and CEO of Timberlyne Therapeutics. His prior roles include Senior Vice President at Takeda Pharmaceutical Company and Vice President at Millennium Pharmaceuticals. Catalyst's Chairman, Patrick J. McEnany, highlighted Dr. Curran's expertise in rare diseases as a significant asset for the company's growth strategy. Dr. Curran expressed his enthusiasm for contributing to Catalyst's mission of delivering innovative therapies for underserved patients. Catalyst is dedicated to improving the lives of those with rare diseases and has been recognized as one of America's most successful mid-cap companies.
Potential Positives
- Dr. Daniel Curran's appointment to the Board of Directors brings over 25 years of pharmaceutical industry experience, particularly in rare diseases, which can enhance Catalyst's strategic initiatives.
- His leadership experience at prestigious companies like Takeda and Millennium Pharmaceuticals may provide valuable insights and connections that could benefit Catalyst's growth strategy and portfolio development.
- Catalyst's recognition as one of America's Most Successful Mid-Cap Companies and one of North America's Fastest-Growing Companies underscores its strong market position and growth potential.
Potential Negatives
- Dr. Curran's simultaneous roles at Timberlyne Therapeutics and Xilio Therapeutics may raise potential conflicts of interest that could complicate his commitment to Catalyst Pharmaceuticals.
- The mention of potential risks and uncertainties in the forward-looking statements section may indicate a lack of confidence in the company's future performance.
- The press release does not provide specific details on how Dr. Curran's appointment will directly impact Catalyst's strategy or operations, leaving questions about the tangible benefits of his addition to the Board.
FAQ
Who is Daniel Curran and what is his role at Catalyst Pharmaceuticals?
Daniel Curran, MD, is a new Board member at Catalyst Pharmaceuticals, bringing over 25 years of pharmaceutical experience.
What experience does Dr. Curran have in the pharmaceutical industry?
Dr. Curran has held senior roles at Takeda and Millennium Pharmaceuticals, focusing on rare diseases and business development.
Why is Dr. Curran's appointment significant for Catalyst Pharmaceuticals?
His expertise in rare disease and strategic asset acquisition will enhance Catalyst's growth and innovative therapy development.
What does Catalyst Pharmaceuticals focus on?
Catalyst is focused on developing, commercializing, and in-licensing therapies for patients with rare diseases.
Where is Catalyst Pharmaceuticals headquartered?
Catalyst Pharmaceuticals is headquartered in Coral Gables, Florida, and has a strong presence in the U.S. market.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CPRX Insider Trading Activity
$CPRX insiders have traded $CPRX stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $CPRX stock by insiders over the last 6 months:
- GARY INGENITO (Chief Med. & Reg. Officer) has made 0 purchases and 4 sales selling 469,000 shares for an estimated $10,670,329.
- PATRICK J MCENANY has made 0 purchases and 2 sales selling 200,000 shares for an estimated $5,217,338.
- RICHARD J DALY (President and CEO) sold 70,000 shares for an estimated $1,740,200
- BRIAN ELSBERND (Chief Compliance/Legal Officer) has made 0 purchases and 2 sales selling 62,975 shares for an estimated $1,446,932.
- CARMEN JEFFREY DEL (Chief Commercial Officer) sold 30,423 shares for an estimated $696,382
- PREETHI SUNDARAM (Chief Strategy Officer) has made 0 purchases and 2 sales selling 3,924 shares for an estimated $103,648.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CPRX Hedge Fund Activity
We have seen 196 institutional investors add shares of $CPRX stock to their portfolio, and 154 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FUNDSMITH LLP added 2,151,274 shares (+inf%) to their portfolio in Q1 2025, for an estimated $52,168,394
- PACER ADVISORS, INC. removed 2,101,141 shares (-71.1%) from their portfolio in Q1 2025, for an estimated $50,952,669
- FIRST TRUST ADVISORS LP removed 1,991,668 shares (-89.2%) from their portfolio in Q1 2025, for an estimated $48,297,949
- DIMENSIONAL FUND ADVISORS LP removed 825,610 shares (-27.4%) from their portfolio in Q1 2025, for an estimated $20,021,042
- METLIFE INVESTMENT MANAGEMENT, LLC added 656,004 shares (+963.5%) to their portfolio in Q1 2025, for an estimated $15,908,097
- BLACKROCK, INC. removed 620,794 shares (-3.2%) from their portfolio in Q1 2025, for an estimated $15,054,254
- VOLORIDGE INVESTMENT MANAGEMENT, LLC removed 419,699 shares (-78.9%) from their portfolio in Q1 2025, for an estimated $10,177,700
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CPRX Analyst Ratings
Wall Street analysts have issued reports on $CPRX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Baird issued a "Outperform" rating on 03/03/2025
- HC Wainwright & Co. issued a "Buy" rating on 02/28/2025
- Stephens & Co. issued a "Overweight" rating on 02/27/2025
To track analyst ratings and price targets for $CPRX, check out Quiver Quantitative's $CPRX forecast page.
$CPRX Price Targets
Multiple analysts have issued price targets for $CPRX recently. We have seen 3 analysts offer price targets for $CPRX in the last 6 months, with a median target of $33.0.
Here are some recent targets:
- Joel Beatty from Baird set a target price of $32.0 on 03/03/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $35.0 on 02/28/2025
- Sudan Loganathan from Stephens & Co. set a target price of $33.0 on 02/27/2025
Full Release
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors.
Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases.
"Dan brings an exceptional combination of strategic insight, rare disease expertise, and business development acumen, making him an outstanding addition to our Board," said Patrick J. McEnany, Chairman of the Board of Catalyst. "His leadership in advancing transformative therapies, paired with a proven history of delivering results across the full development continuum, will be instrumental as Catalyst continues to execute its disciplined growth strategy, which includes maximizing our current rare disease portfolio and acquiring strategically aligned assets."
From 2008 to 2023, Dr. Curran held roles of increasing responsibility at Takeda Pharmaceutical Company, serving as Senior Vice President and Head of the Rare Genetics and Hematology Therapeutic Area Unit from January 2019 through December 2023.
"I'm honored to join the Board of Catalyst and support its mission to deliver innovative therapies to patients with serious and underserved conditions," said Dr. Curran. "Catalyst has built a strong foundation through disciplined execution and strategic asset acquisition, and I look forward to contributing to the Company's continued growth and long-term value creation."
Prior to his tenure at Takeda, Dr. Curran served as Vice President of Corporate Development at Millennium Pharmaceuticals, Inc., from 1999 to 2008. Earlier in his career, he held a business development role in the product planning and acquisition group at DuPont Merck Pharmaceuticals.
Dr. Curran previously served on the board of directors of Tome Biosciences, a private biotechnology company, and currently serves on the Board of Directors of Xilio Therapeutics, Inc. (NASDAQ: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments.
Dr. Curran received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School of the University of Pennsylvania, and a B.S. in chemistry from King's College.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com .
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this Date.
Source: Catalyst Pharmaceuticals, Inc.
